B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals

International Immunology

Volumn 22, Issue 8, 2010, Pages 681-691

  Smith, Susan H ^a   Haas, Karen M ^a,c   Poe, Jonathan C ^a   Yanaba, Koichi ^a,d   Ward, Christopher D ^b   Migone, Thi Sau ^b   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B cell depletion; B cell homeostasis; BLyS BAFF; CD22; mAb therapy

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL ACTIVATING FACTOR RECEPTOR 3; CASPASE 3; CD22 ANTIGEN; CD40 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BLOOD CELL; BONE MARROW CELL; C57BL 6 MOUSE; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD22; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HOMEOSTASIS; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77955027018     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq055     Document Type: Article

References (52)

1. Tedder, T. F., Tuscano, J., Sato, S. and Kehrl, J. H. 1997. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 15:481.
2. Nitschke, L., Carsetti, R., Ocker, B., Kohler, G. and Lamers, M. C. 1997. CD22 is a negative regulator of B-cell receptor signaling. Curr. Biol. 7:133.
3. Lentz, V. M., Hayes, C. E. and Cancro, M. P. 1998. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J. Immunol. 160:3743.
4. Harless, S. M., Lentz, V. M., Sah, A. P. et al. 2001. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr. Biol. 11:1986.
5. Schiemann, B., Gommerman, J. L., Vora, K. et al. 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111.
6. Gordon, J. 1995. CD40 and its ligand: central players in B lymphocyte survival, growth, and differentiation. Blood Rev. 9:53.
7. Kawabe, T., Naka, T., Yoshida, K. et al. 1994. The immune responses in the CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167.
8. Lam, K. P., Kuhn, R. and Rajewsky, K. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90:1073.
9. Sato, S., Miller, A. S., Inaoki, M. et al. 1996. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5:551.
10. Otipoby, K. L., Andersson, K. B., Draves, K. E. et al. 1996. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384:634.
11. O'Keefe, T. L., Williams, G. T., Davies, S. L. and Neuberger, M. S. 1996. Hyperresponsive B cells in CD22-deficient mice. Science 274:798.
12. Poe, J. C., Fujimoto, Y., Hasegawa, M. et al. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5:1078.
13. Haas, K. M., Sen, S., Sanford, I. G., Miller, A. S., Poe, J. C. and Tedder, T. F. 2006. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J. Immunol. 177:3063.
14. Fujimoto, M., Bradney, A. P., Poe, J. C., Steeber, D. A. and Tedder, T. F. 1999. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 11:191.
15. Treml, J. F., Hao, Y., Stadanlick, J. E. and Cancro, M. P. 2009. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem. Biophys. 53:1.
16. Moore, P. A., Belvedere, O., Orr, A. et al. 1999. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260.
17. Schneider, P., MacKay, F., Steiner, V. et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189:1747.
18. Yan, M., Marsters, S. A., Grewal, I. S., Wang, H., Ashkenazi, A. and Dixit, V. M. 2000. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol. 1:37.
19. Wu, Y., Bressette, D., Carrell, J. A. et al. 2000. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J. Biol. Chem. 275:35478.
20. Marsters, S. A., Yan, M., Pitti, R. M., Haas, P. E., Dixit, V. M. and Ashkenazi, A. 2000. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. 10:785.
21. Lentz, V. M., Cancro, M. P., Nashold, F. E. and Hayes, C. E. 1996. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J. Immunol. 157:598.
22. Yan, M., Brady, J. R., Chan, B. et al. 2001. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11:1547.
23. Gross, J. A., Dillon, S. R., Mudri, S. et al. 2001. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15:289.
24. Scholz, J. L., Crowley, J. E., Tomayko, M. M. et al. 2008. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad. Sci. USA. 105:15517.
25. Thien, M., Phan, T. G., Gardam, S. et al. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785.
26. Do, R. K., Hatada, E., Lee, H., Tourigny, M. R., Hilbert, D. and Chen-Kiang, S. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192:953.
27. Groom, J., Kalled, S. L., Cutler, A. H. et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109:59.
28. Mackay, F., Woodcock, S. A., Lawton, P. et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697.
29. Cheema, G. S., Roschke, V., Hilbert, D. M. and Stohl, W. 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44:1313.
30. Matsushita, T., Hasegawa, M., Yanaba, K., Kodera, M., Takehara, K. and Sato, S. 2006. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54:192.
31. Gross, J. A., Johnston, J., Mudri, S. et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995.
32. Anolik, J. H., Barnard, J., Cappione, A. et al. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50:3580.
33. Looney, R. J., Anolik, J. H., Campbell, D. et al. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50:2580.
34. Hasegawa, M., Hamaguchi, Y., Yanaba, K. et al. 2006. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169:954.
35. + T cell activation in mice. Proc. Natl Acad. Sci. USA. 104:20882.
36. Hu, C., Deng, S., Wong, F. S. and Wen, L. 2008. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes. Ann. N. Y. Acad. Sci. 1150:217.
37. Poe, J. C., Haas, K. M., Uchida, J., Lee, Y., Fujimoto, M. and Tedder, T. F. 2004. Severely-impaired B lymphocyte proliferation, survival and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. J. Immunol. 172:2100.
38. Fang, W., Mueller, D. L., Pennell, C. A. et al. 1996. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity 4:291.
39. Zekavat, G., Rostami, S. Y., Badkerhanian, A. et al. 2008. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol. 181:8133.
40. Uchida, J., Lee, Y., Hasegawa, M. et al. 2004. Mouse CD20 expression and function. Int. Immunol. 16:119.
41. Amanna, I. J., Dingwall, J. P. and Hayes, C. E. 2003. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J. Immunol. 170:4593.
42. Uchida, J., Hamaguchi, Y., Oliver, J. A. et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659.
43. O'Connor, B. P., Raman, V. S., Erickson, L. D. et al. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199:91.
44. Hsu, B. L., Harless, S. M., Lindsley, R. C., Hilbert, D. M. and Cancro, M. P. 2002. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168:5993.
45. Rahman, Z. S. and Manser, T. 2004. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J. Immunol. 173:6179.
46. Sasaki, Y., Casola, S., Kutok, J. L., Rajewsky, K. and Schmidt-Supprian, M. 2004. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173:2245.
47. Grewal, P. K., Boton, M., Ramirez, K. et al. 2006. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol. Cell. Biol. 26:4970.
48. Schneider, P., Takatsuka, H., Wilson, A. et al. 2001. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194:1691.
49. Harris, M. H. and Thompson, C. B. 2000. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7:1182.
50. Cambridge, G., Stohl, W., Leandro, M. J., Migone, T. S., Hilbert, D. M. and Edwards, J. C. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54:723.
51. Lavie, F., Miceli-Richard, C., Ittah, M., Sellam, J., Gottenberg, J. E. and Mariette, X. 2007. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66:700.
52. Mackay, F., Silveira, P. A. and Brink, R. 2007. B cells and the BAFF/ APRIL axis: fast-forward on autoimmunity and signaling. Curr. Opin. Immunol. 19:327.